Transcode Therapeutics Inc (RNAZ)

$0.27 -0.08 (-23.58%)
Market Cap 6.36M
Revenue (ttm) 0.00
Net Income (ttm) -18.55M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 5,689,000
Avg Vol 7,680,616
Day's Range N/A - N/A
Shares Out 23.34M
Stochastic %K 21%
Beta 1.51
Analysts Strong Sell
Price Target $10.00

Latest News on RNAZ

TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138

Mar 27, 2025, 4:37 PM EDT - 23 days ago

TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138

TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering

Mar 25, 2025, 6:24 PM EDT - 25 days ago

TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering

TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Mar 23, 2025, 11:11 PM EDT - 27 days ago

TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial

Mar 13, 2025, 7:47 AM EDT - 5 weeks ago

TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial

TransCode Therapeutics, Inc. Announces Results of Special Meeting

Feb 25, 2025, 4:15 PM EST - 7 weeks ago

TransCode Therapeutics, Inc. Announces Results of Special Meeting

TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial

Feb 6, 2025, 8:00 AM EST - 2 months ago

TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial

TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting

Feb 4, 2025, 4:15 PM EST - 2 months ago

TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting

TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial

Jan 14, 2025, 8:00 AM EST - 3 months ago

TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial

Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements

Jan 7, 2025, 8:00 AM EST - 3 months ago

Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements

TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial

Dec 18, 2024, 8:00 AM EST - 4 months ago

TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial

TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split

Nov 29, 2024, 4:25 PM EST - 5 months ago

TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split

TransCode Therapeutics, Inc. Announces $8 Million Private Placement

Nov 27, 2024, 7:00 AM EST - 5 months ago

TransCode Therapeutics, Inc. Announces $8 Million Private Placement

TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance

Nov 5, 2024, 7:00 AM EST - 5 months ago

TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance

TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate

Sep 17, 2024, 7:00 AM EDT - 7 months ago

TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate

TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate

Sep 5, 2024, 7:00 AM EDT - 8 months ago

TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate

TransCode Therapeutics, Inc. Announces Closing of Public Offering

Jul 24, 2024, 4:05 PM EDT - 9 months ago

TransCode Therapeutics, Inc. Announces Closing of Public Offering

TransCode Therapeutics, Inc. Announces Pricing of Public Offering

Jul 22, 2024, 10:30 PM EDT - 9 months ago

TransCode Therapeutics, Inc. Announces Pricing of Public Offering

TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

Jul 22, 2024, 4:07 PM EDT - 9 months ago

TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138

May 29, 2024, 9:15 AM EDT - 11 months ago

TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138

TransCode Therapeutics Open Letter to Shareholders

May 13, 2024, 8:30 AM EDT - 1 year ago

TransCode Therapeutics Open Letter to Shareholders

TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors

Apr 15, 2024, 9:00 AM EDT - 1 year ago

TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors

TransCode Therapeutics Reports 2023 Results; Provides Business Update

Apr 3, 2024, 9:10 AM EDT - 1 year ago

TransCode Therapeutics Reports 2023 Results; Provides Business Update

TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer

Mar 28, 2024, 8:30 AM EDT - 1 year ago

TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer

TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment

Mar 11, 2024, 9:00 AM EDT - 1 year ago

TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment

TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress

Mar 6, 2024, 4:15 PM EST - 1 year ago

TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress

TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode's RIG-I Agonist Immunotherapeutic

Feb 20, 2024, 8:00 AM EST - 1 year ago

TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode's RIG-I Agonist Immunotherapeutic

Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders' Equity Requirement and Continued Listing on The Nasdaq Stock Market

Jan 31, 2024, 4:05 PM EST - 1 year ago

Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders' Equity Requirement and Continued Listing on The Nasdaq Stock Market

TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer

Jan 29, 2024, 8:30 AM EST - 1 year ago

TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer

TransCode Therapeutics Announces Closing of $7.25 Million Public Offering

Jan 22, 2024, 4:45 PM EST - 1 year ago

TransCode Therapeutics Announces Closing of $7.25 Million Public Offering

TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering

Jan 18, 2024, 1:27 PM EST - 1 year ago

TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering

TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO

Jan 12, 2024, 4:05 PM EST - 1 year ago

TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO

TransCode Therapeutics Announces 1-for-40 Reverse Stock Split

Jan 11, 2024, 8:00 AM EST - 1 year ago

TransCode Therapeutics Announces 1-for-40 Reverse Stock Split

TransCode Therapeutics Publishes Open Letter Outlining Company's Progress and Objectives

Jan 4, 2024, 8:05 AM EST - 1 year ago

TransCode Therapeutics Publishes Open Letter Outlining Company's Progress and Objectives

TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138

Dec 12, 2023, 8:30 AM EST - 1 year ago

TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138

TransCode Therapeutics To Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium

Dec 5, 2023, 9:00 AM EST - 1 year ago

TransCode Therapeutics To Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium

TransCode Therapeutics Announces Closing of $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules

Dec 4, 2023, 4:10 PM EST - 1 year ago

TransCode Therapeutics Announces Closing of $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules

TransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules

Nov 30, 2023, 2:53 PM EST - 1 year ago

TransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules

TransCode Therapeutics Reports Third Quarter 2023 Results; Provides Business Update

Nov 14, 2023, 4:30 PM EST - 1 year ago

TransCode Therapeutics Reports Third Quarter 2023 Results; Provides Business Update

TransCode Therapeutics Withdraws Public Offering

Oct 30, 2023, 4:33 PM EDT - 1 year ago

TransCode Therapeutics Withdraws Public Offering

Nasdaq Panel Grants TransCode Therapeutics Extension for Continued Listing on The Nasdaq Stock Market Subject to Conditions

Oct 27, 2023, 8:00 AM EDT - 1 year ago

Nasdaq Panel Grants TransCode Therapeutics Extension for Continued Listing on The Nasdaq Stock Market Subject to Conditions

TransCode Therapeutics Announces Public Offering of Common Stock

Oct 26, 2023, 4:19 PM EDT - 1 year ago

TransCode Therapeutics Announces Public Offering of Common Stock

TransCode Therapeutics Announces Prolonged Survival in Murine Models with Glioblastoma Treated with Its Lead Candidate, TTX-MC138

Oct 26, 2023, 8:00 AM EDT - 1 year ago

TransCode Therapeutics Announces Prolonged Survival in Murine Models with Glioblastoma Treated with Its Lead Candidate, TTX-MC138

TransCode Therapeutics Announces Preliminary Clinical Results in First Patient in Phase 0 Clinical Study with Lead Therapeutic Candidate, TTX-MC138

Oct 24, 2023, 8:00 AM EDT - 1 year ago

TransCode Therapeutics Announces Preliminary Clinical Results in First Patient in Phase 0 Clinical Study with Lead Therapeutic Candidate, TTX-MC138

TransCode Therapeutics Reports Successful Treatment of Preclinical Melanoma Tumors with its Immunotherapy Candidate, TTX-RIGA

Oct 16, 2023, 8:00 AM EDT - 1 year ago

TransCode Therapeutics Reports Successful Treatment of Preclinical Melanoma Tumors with its Immunotherapy Candidate, TTX-RIGA

TransCode Therapeutics Announces Closing of $8.5 Million Public Offering

Sep 28, 2023, 4:02 PM EDT - 1 year ago

TransCode Therapeutics Announces Closing of $8.5 Million Public Offering

TransCode Therapeutics Announces Pricing of $8 Million Public Offering

Sep 25, 2023, 8:01 PM EDT - 1 year ago

TransCode Therapeutics Announces Pricing of $8 Million Public Offering

TransCode Therapeutics Announces Positive Pre-Clinical Glioblastoma Results with Lead Therapeutic Candidate, TTX-MC138

Sep 25, 2023, 8:30 AM EDT - 1 year ago

TransCode Therapeutics Announces Positive Pre-Clinical Glioblastoma Results with Lead Therapeutic Candidate, TTX-MC138

TransCode Therapeutics Announces First Subject Dosed with Radiolabeled TTX-MC138 in First-In-Human Clinical Trial

Aug 23, 2023, 8:00 AM EDT - 1 year ago

TransCode Therapeutics Announces First Subject Dosed with Radiolabeled TTX-MC138 in First-In-Human Clinical Trial

TransCode Therapeutics Reports Second Quarter 2023 Results; Provides Business Update

Aug 14, 2023, 4:45 PM EDT - 1 year ago

TransCode Therapeutics Reports Second Quarter 2023 Results; Provides Business Update

TransCode Therapeutics Announces Positive Results in Non-human Primates with its Lead Therapeutic Candidate, TTX-MC138

Jul 31, 2023, 7:00 AM EDT - 1 year ago

TransCode Therapeutics Announces Positive Results in Non-human Primates with its Lead Therapeutic Candidate, TTX-MC138